Assignment at the Institute for Biometry by phone. This

Assignment at the Institute for Biometry by phone. This PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/10512904 procedure allows the statement to be made that the operation prior to the application of EVICELTM is concealed and performed without any bias. In this RCT, the patients will be blinded but owing to the nature of the intervention the surgeons clearly cannot be blinded. The treating surgeons will conduct the therapy in a way that complies with the single-blinded design of the study. In the rare case of a spinal anaesthesia, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12958591 it will be ensured that patients will have no opportunity to realise whether they receive the medicinal product under investigation (IMP) or not. The medical team involved in theAs the application of EVICELTM is conducted only at a single time point in a three-step procedure, subjects cannot be withdrawn from the IMP treatment. The only exceptions are complications occurring during the operation, leading to an 2-(2,4-Dichloro-5-fluorophenyl)oxirane immediate cessation of EVICELTM use. Patients undergoing a thromboembolic or any other event demanding anticoagulation that exceeds the standard prophylaxis measures during the first 7 days after surgery will be recorded as having the smallest Hb value before anticoagulation. Patients receiving anticoagulation during the operation will be recorded as having the largest Hb difference of the control group. The same procedure applies to patients receiving any kind of blood product during or after the operation. Because in nearly all cases there will be a blood sample collection prior to a transfusion or to a change in anticoagulation medication, these patients are expected to account for 2 h) will not be enrolled. In most cases, it is foreseeable before randomisation that the operation will probably take longer than 2 h; therefore, those patients will not be randomised, and the percentage 2-(2,4-Dichloro-5-fluorophenyl)oxirane of subjects not included because of the duration of surgery is expected to be <1 .InsuranceMandatory patient insurance for this trial according to AMG ?40 (3) has been obtained. Because of this, any damage to patient health during the conduct of theBudde et al. Trials (2015) 16:Page 8 ofstudy will be insured, with a maximum amount of coverage of 500,000 per patient. This covers all damage that may occur to the patient either indirectly or directly as a result of the study medication or interventions in connection with the RCT.Overview of the medical product under investigationEVICELTM is a fibrin sealant kit c.